Startup profile for TriGemX Bio: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

TriGemX Bio funding, valuation and investors

Late-stage migraine biotech developing elismetrep, an oral TRPM8 channel blocker.

Verified company research · funding, investors and latest developments

Keep track of TriGemX Bio

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Financing (stage undisclosed)

$94M · October 1, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$94M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · New York, New York

Investors in latest funding

Lead: The Column Group , TCGX , Viking Global Investors

Sources: latest funding · trigemxbio.com Last verified: 2026-10-05T07:15:00Z

Overview

TriGemX Bio, formerly Kallyope, is a New York biotechnology company advancing elismetrep for the acute treatment of migraine. Elismetrep is an investigational oral blocker of the TRPM8 ion channel and is in Phase 3 trials.

Why TriGemX Bio is interesting

The $94 million financing funds an active pivotal program rather than early discovery. TriGemX is testing a mechanistically distinct migraine target after a positive Phase 2b study, with first Phase 3 results expected in mid-2027. The central risk is binary clinical and regulatory execution: elismetrep remains investigational and has not been approved.

Product & use cases

Elismetrep (K-304), a liquid-filled soft-gel formulation of an oral TRPM8 channel blocker for acute migraine treatment.

  • Acute treatment of migraine in adults.

Key facts

  • Closed $94 million of financing co-led by The Column Group, TCGX and Viking Global Investors.
  • Two pivotal studies and a long-term safety study form the Phase 3 program.
  • Relaunched from Kallyope as TriGemX Bio with a focused migraine strategy and new leadership.

Funding history (newest first)

Investors in our directory

Funds linked from TriGemX Bio's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: A potentially first-in-class oral TRPM8 blocker with Phase 2b evidence and an active pivotal program.

TriGemX will compete for use in a migraine market transformed by CGRP-targeted drugs from AbbVie, Pfizer and Eli Lilly, alongside triptans and other acute therapies. Its argument is mechanistic differentiation through TRPM8 blockade. Commercial value will depend on Phase 3 efficacy, safety, onset and tolerability relative to established oral options.

  • AbbVie (Ubrelvy) incumbent

    Established oral CGRP antagonist for acute migraine treatment.

  • Pfizer (Nurtec ODT) incumbent

    Oral CGRP antagonist used for acute treatment and prevention.

  • Eli Lilly (Reyvow) alternative

    Non-CGRP oral acute migraine treatment with a distinct mechanism.

  • Triptans alternative

    Long-established acute migraine therapies used broadly as generics and brands.

Industries

Market / IPO context

Editorial / static context — not a live quote.

FAQs about TriGemX Bio

Practical answers founders, operators, and investors typically search for.

TriGemX Bio closed a $94 million financing announced on October 1, 2026. The formal venture stage was not disclosed.
The Column Group, TCGX and Viking Global Investors co-led the financing.
Elismetrep, also known as K-304, is an investigational oral TRPM8 channel blocker being studied for acute migraine treatment.
TriGemX expects initial results from its first Phase 3 trial in mid-2027.
No. Elismetrep remains investigational and has not been approved by the FDA or another regulatory agency.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.